This issue can be partly solved by using GDNF and NRTN variants which have been shown to have better tissue diffusion and stability (Runeberg-Roos et al. 2016; Grondin et al. 2019) Therefore, these variants can be considered as potential candidates for treating PD patients. This evidence concerns the gene NRTN and Parkinson disease.